TransUnion Q3 2026 slides: insurance drives growth amid margin pressure

TransUnion reported Q3 adjusted EPS of $1.25, 3.3% above Wall Street’s $1.21 estimate, while revenue of $1.31B matched forecasts; organic constant-currency revenue grew 8% and adjusted EPS rose 14% year over year. The company raised FY2026 adjusted EPS guidance to $4.81–$4.88 and expects 8%–9% organic constant-currency revenue growth, but adjusted EBITDA margin fell 90 bps to 35.4% and Q4 mortgage inquiries are expected to decline more than 20%. Shares fell 2.19% to $77.88 in premarket trading as investors weighed margin pressure and mortgage headwinds against the stronger outlook; the board also increased its buyback authorization by $1B to $2B.

Analysis

The key tension is not the beat; it is the gap between full-year confidence and a softer near-term growth cadence. Q4 organic growth guidance implies deceleration from Q3, so the raised annual outlook depends on execution and a stronger contribution from international markets—not simply a mortgage rebound. If investors treat the guide raise as proof of durable acceleration, they may be underpricing that cadence risk.

The 90 bp margin decline is not wholly structural: management attributes much of it to no-margin FICO royalties and deliberate technology investment. But the relevant test is whether underlying margin expansion resumes while OneTru migration finishes. Migration could lower operating friction over time; delays or parallel-run costs would convert an investment narrative into persistent margin leakage. Treat the stated product revenue potential as unproven until it appears in reported results.

Insurance and international growth reduce reliance on U.S. mortgage activity, but the awarded insurance pipeline is a 2–3 year conversion story, not an immediate earnings offset. The second-order risk is that elevated rates affect not only mortgage inquiries but also broader lending activity and customer acquisition budgets. Legal/regulatory expense adds a separate, harder-to-time margin risk.

Near term, the market is likely to focus on Q4 organic growth and mortgage volume; over 1–3 months, execution against guidance matters more than buyback authorization. Over 6–18 months, platform migration and insurance backlog conversion determine whether growth can fund margin expansion. No valuation data is provided, so the post-reaction price alone does not establish a bargain.

Key Decisions for Investors

• Do not chase the earnings beat. Consider a staged long in TRU only after Q4 results or an interim update confirms organic growth is tracking guidance and underlying margins are stabilizing; upside would come from reduced mortgage dependence and operating leverage, while downside is a further growth or margin reset.
• Use Q4 organic revenue growth, mortgage inquiry trends, and adjusted EBITDA margin as the near-term monitoring set. A miss against the company’s own Q4 ranges, or evidence that margin pressure persists beyond royalty mix and planned investment, would falsify the constructive thesis.
• Treat insurance contract wins and management’s new-product revenue estimate as watch items, not booked growth. Look for disclosed conversion into recognized revenue over coming quarters before underwriting them in forecasts.
• For a relative-value screen, compare TRU’s organic growth and margin trajectory with Equifax and Experian before initiating a pair; the supplied information is insufficient to establish a valuation or operating-quality divergence.